{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:05:31Z","timestamp":1781726731926,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008402","name":"Chengdu University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["LH202402044"],"award-info":[{"award-number":["LH202402044"]}],"id":[{"id":"10.13039\/501100008402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008402","name":"Chengdu University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["WXLH202403008"],"award-info":[{"award-number":["WXLH202403008"]}],"id":[{"id":"10.13039\/501100008402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013792","name":"Chengdu University","doi-asserted-by":"publisher","award":["QJRC2022028"],"award-info":[{"award-number":["QJRC2022028"]}],"id":[{"id":"10.13039\/501100013792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013792","name":"Chengdu University","doi-asserted-by":"publisher","award":["QJJJ2024005"],"award-info":[{"award-number":["QJJJ2024005"]}],"id":[{"id":"10.13039\/501100013792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.phymed.2025.157246","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T03:45:58Z","timestamp":1757648758000},"page":"157246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Comparison of the efficacy and action mechanism of Chinese patent medicines for liver fibrosis and cirrhosis"],"prefix":"10.1016","volume":"148","author":[{"given":"Lingping","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZeXin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengshuang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailai","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0261-0369","authenticated-orcid":false,"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5860-3790","authenticated-orcid":false,"given":"Jinhao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Efferth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2025.157246_bib0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.coviro.2016.07.008","article-title":"KSHV non-structural membrane proteins involved in the activation of intracellular signaling pathways and the pathogenesis of Kaposi\u2019s sarcoma","volume":"20","author":"Abere","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.phymed.2025.157246_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173010","article-title":"Olmesartan attenuates type 2 diabetes-associated liver injury: cross-talk of AGE\/RAGE\/JNK, STAT3\/SCOS3 and RAS signaling pathways","volume":"874","author":"Abo El- Nasr","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phymed.2025.157246_bib0003","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","article-title":"Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts","volume":"17","author":"Alexander","year":"2019","journal-title":"BMC. Med."},{"key":"10.1016\/j.phymed.2025.157246_bib0004","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcv.2009.05.009","article-title":"Prevalence of human cytomegalovirus co-infection in patients with chronic viral hepatitis B and C: a comparison of clinical and histological aspects","volume":"45","author":"Bayram","year":"2009","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.phymed.2025.157246_bib52","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1182\/blood.V128.22.5429.5429","article-title":"Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors","volume":"128","author":"Benjamini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.phymed.2025.157246_bib0006","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1128\/JVI.77.7.4033-4042.2003","article-title":"Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB","volume":"77","author":"Biermer","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.phymed.2025.157246_bib0007","doi-asserted-by":"crossref","first-page":"e1592","DOI":"10.1097\/TXD.0000000000001592","article-title":"Elevated plasma CXCL8 concentrations in significant fibrosis but not in subclinical rejection after adult liver transplantation","volume":"10","author":"Campos-Murguia","year":"2024","journal-title":"TransPlant Direct."},{"key":"10.1016\/j.phymed.2025.157246_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148111","article-title":"Immune checkpoints on T and NK cells in the context of HBV infection: landscape, pathophysiology and therapeutic exploitation","volume":"14","author":"Dumolard","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phymed.2025.157246_bib0009","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3390\/medicina59071287","article-title":"The relationship between mean platelet volume and neutrophil-lymphocyte ratio and liver fibrosis in patients with chronic hepatitis B","volume":"59","author":"Ekmen","year":"2023","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.phymed.2025.157246_bib0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri2569","article-title":"Signalling through C-type lectin receptors: shaping immune responses","volume":"9","author":"Geijtenbeek","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phymed.2025.157246_bib0011","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-pharmtox-020524-012013","article-title":"Immunoregulation of liver fibrosis: new opportunities for antifibrotic therapy","volume":"65","author":"Gilgenkrantz","year":"2025","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.phymed.2025.157246_bib0012","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.phymed.2025.157246_bib0013","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phymed.2025.157246_bib0014","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2025.157246_bib0015","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1161\/CIRCRESAHA.121.319540","article-title":"Deletion of BACH1 attenuates atherosclerosis by reducing endothelial inflammation","volume":"130","author":"Jia","year":"2022","journal-title":"Circ. Res."},{"key":"10.1016\/j.phymed.2025.157246_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2023.114010","article-title":"Dietary N\u03b5-(carboxymethyl)lysine is a trigger of non-alcoholic fatty liver disease under high-fat consumption","volume":"180","author":"Lee","year":"2023","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.phymed.2025.157246_bib0017","doi-asserted-by":"crossref","first-page":"S638","DOI":"10.1016\/S0168-8278(23)01978-5","article-title":"Diabetes mellitus (DM) is the strongest risk factor of significant inflammation or fibrosis in chronic hepatitis B (CHB) combined with non-alcoholic fatty liver disease (NAFLD)","volume":"78","author":"Li","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2025.157246_bib0018","doi-asserted-by":"crossref","first-page":"S696","DOI":"10.1016\/S0168-8278(23)02069-X","article-title":"A diagnostic non-invasive model for liver advanced fibrosis and cirrhosis in chronic hepatitis B (CHB) concurrent with non-alcoholic fatty liver disease (NAFLD) based on machine learning (ML)","volume":"78","author":"Li","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2025.157246_bib0019","first-page":"4090","article-title":"Serum CHI3L1 as a diagnostic marker and risk factor for liver fibrosis in HBeAg-negative chronic hepatitis B","volume":"14","author":"Li","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.phymed.2025.157246_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1303012","article-title":"Research progress of Traditional Chinese Medicine in improving hepatic fibrosis based on inhibiting pathological angiogenesis","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phymed.2025.157246_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110908","article-title":"Gas7 attenuates hepatocellular carcinoma progression and chemoresistance through the PI3K\/Akt signaling pathway","volume":"112","author":"Liu","year":"2023","journal-title":"Cell Signal."},{"key":"10.1016\/j.phymed.2025.157246_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172946","article-title":"Platycodin D alleviates liver fibrosis and activation of hepatic stellate cells by regulating JNK\/c-JUN signal pathway","volume":"876","author":"Liu","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phymed.2025.157246_bib0023","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.2147\/DMSO.S426102","article-title":"Liver fibrosis scores and coronary artery disease: novel findings in patients with metabolic dysfunction-associated fatty liver disease","volume":"16","author":"Lu","year":"2023","journal-title":"Diabetes. Metab. Syndr. Obes."},{"key":"10.1016\/j.phymed.2025.157246_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115615","article-title":"TANGO1 interacts with NRTN to promote hepatocellular carcinoma progression by regulating the PI3K\/AKT\/mTOR signaling pathway","volume":"213","author":"Man","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phymed.2025.157246_bib0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/030006059302100306","article-title":"Liver pathology in cytomegalovirus infection associated with hepatitis B virus","volume":"21","author":"Marinelli","year":"1993","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.phymed.2025.157246_bib0026","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cld.2015.01.001","article-title":"Global epidemiology of hepatocellular carcinoma","volume":"19","author":"McGlynn","year":"2015","journal-title":"Clin. Liver. Dis."},{"key":"10.1016\/j.phymed.2025.157246_bib0027","article-title":"Association of liver fibrosis with cardiovascular diseases in the general population: the multi-ethnic study of atherosclerosis (MESA)","volume":"117","author":"Ostovaneh","year":"2018","journal-title":"Circ. Cardiovasc. ImAging"},{"key":"10.1016\/j.phymed.2025.157246_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygeno.2024.110800","article-title":"Identification of STAT3 as a biomarker for cellular senescence in liver fibrosis: a bioinformatics and experimental validation study","volume":"116","author":"Pang","year":"2024","journal-title":"Genomics"},{"key":"10.1016\/j.phymed.2025.157246_bib0029","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jgr.2022.03.003","article-title":"Integrative applications of network pharmacology and molecular docking: an herbal formula ameliorates H9c2 cells injury through pyroptosis","volume":"47","author":"Qi","year":"2023","journal-title":"J. Ginseng. Res."},{"key":"10.1016\/j.phymed.2025.157246_bib0030","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3390\/livers2040028","article-title":"Liver fibrosis, Liver cancer, and advances in therapeutic approaches","volume":"2","author":"Rajapaksha","year":"2022","journal-title":"Livers."},{"key":"10.1016\/j.phymed.2025.157246_bib0031","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.celrep.2015.10.058","article-title":"Dectin-1 regulates hepatic fibrosis and hepatocarcino genesis by suppressing TLR4 signaling pathways","volume":"13","author":"Seifert","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.phymed.2025.157246_bib0032","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Sepanlou","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.phymed.2025.157246_bib0033","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.gastha.2023.02.004","article-title":"Enhancing hepatic MBOAT7 expression in mice with nonalcoholic steatohepatitis","volume":"2","author":"Sharpe","year":"2023","journal-title":"Gastro Hep. Adv."},{"key":"10.1016\/j.phymed.2025.157246_bib0034","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/S0168-8278(20)30722-4","article-title":"Toll-like receptor 4 signaling in bone marrow-derived macrophage promotes resolution of carbon tetrachloride-induced murine liver fibrosis","volume":"73","author":"Takimoto","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.phymed.2025.157246_bib51","doi-asserted-by":"crossref","first-page":"7815","DOI":"10.1007\/s11033-023-08666-0","volume":"50","author":"Tamber","year":"2023","journal-title":"Biomarkers of liver diseases. Mol Biol Rep."},{"key":"10.1016\/j.phymed.2025.157246_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinsp.2023.100301","article-title":"Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation","volume":"78","author":"Tan","year":"2023","journal-title":"Clinics."},{"key":"10.1016\/j.phymed.2025.157246_bib0036","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5530\/ijpcs.4.4.4","article-title":"Comparison of in vitro antioxidant activity of olmesartan and amlodipine","volume":"4","author":"Thiruvengadam","year":"2016","journal-title":"Int. J. Pharmacol. Clin. Sci"},{"key":"10.1016\/j.phymed.2025.157246_bib0037","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/jebm.12443","article-title":"Progress and challenges of network meta-analysis","volume":"14","author":"Tian","year":"2021","journal-title":"J. Evid. Based. Med."},{"key":"10.1016\/j.phymed.2025.157246_bib0038","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1016\/j.apsb.2022.03.014","article-title":"Inhibition of ASCT2 induces hepatic stellate cell senescence with modified proinflammatory secretome through an IL-1\u03b1\/NF-\u03bab feedback pathway to inhibit liver fibrosis","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phymed.2025.157246_bib0039","first-page":"7831","article-title":"Anhydroicaritin suppresses tumor progression via the PI3K\/AKT signaling pathway in hepatocellular carcinoma","volume":"15","author":"Wang","year":"2023","journal-title":"Aging (Albany. NY)"},{"key":"10.1016\/j.phymed.2025.157246_bib0040","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fphar.2020.00388","article-title":"Antifibrotic effects of a barbituric acid derivative on liver fibrosis by blocking the NF-\u03bab signaling pathway in hepatic stellate cells","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phymed.2025.157246_bib0041","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1210\/er.2019-00034","article-title":"The liver as an endocrine organ\u2014Linking NAFLD and insulin resistance","volume":"40","author":"Watt","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.phymed.2025.157246_bib0042","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.canlet.2009.07.004","article-title":"Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis","volume":"289","author":"Wen","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phymed.2025.157246_bib0043","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1136\/gutjnl-2016-313392","article-title":"The HLF\/IL-6\/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis","volume":"67","author":"Xiang","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.phymed.2025.157246_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.771046","article-title":"Biejiajian Pill promotes the infiltration of CD8+ T cells in hepatocellular carcinoma by regulating the expression of CCL5","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phymed.2025.157246_bib0045","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3350\/cmh.2022.0322","article-title":"Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase","volume":"29","author":"Yoo","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.phymed.2025.157246_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1217023","article-title":"Management of chronic myelogenous leukemia with COVID-19 and hepatitis B","volume":"13","author":"Yu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phymed.2025.157246_bib0047","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/436450","article-title":"Therapeutic potential of IL-17-mediated signaling pathway in autoimmune liver diseases","volume":"2015","author":"Zhang","year":"2015","journal-title":"Mediators. Inflamm."},{"key":"10.1016\/j.phymed.2025.157246_bib0048","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41419-023-06324-8","article-title":"The C-type lectin COLEC10 is predominantly produced by hepatic stellate cells and involved in the pathogenesis of liver fibrosis","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.phymed.2025.157246_bib0049","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/jcmm.16209","article-title":"Hepatic stellate cells specific liposomes with the toll-like receptor 4 shRNA attenuates liver fibrosis","volume":"25","author":"Zhang","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.phymed.2025.157246_bib0050","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1055\/s-0040-1722186","article-title":"Tumor necrosis factor-\u03b1 blockade corrects monocyte\/macrophage imbalance in primary immune thrombocytopenia","volume":"121","author":"Zhao","year":"2021","journal-title":"Thromb. Haemost."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711325008852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711325008852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:19:03Z","timestamp":1778559543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711325008852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":51,"alternative-id":["S0944711325008852"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2025.157246","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the efficacy and action mechanism of Chinese patent medicines for liver fibrosis and cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2025.157246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"157246"}}